Skip to main content
. 2014 Sep 22;9(9):e107487. doi: 10.1371/journal.pone.0107487

Figure 3. IL1Ra ASO treatment reduces liver triglyceride and improved liver inflammation.

Figure 3

A) Liver weight (g), B) H&E stain of liver. C) Liver triglyceride content after 6 weeks of IL-1Ra ASO or control ASO treatment in HFD fed mice. D) QPCR analysis of inflammatory gene expression in the liver of obese mice treated with IL-1Ra ASO or control ASO, results are normalized to beta actin mRNA and expressed relative to control ASO treatment. * p<0.05 compared to HFD-fed control treated group, nā€Š=ā€Š5āˆ’8 mice per group.